Table 3.
Ongoing clinical trials with targeted therapies including patients with activating FLT3 mutations.
| ClinicalTrials.gov Identifier | Drug Combination | Targets (Inhibition) | Phase | n | AML |
|---|---|---|---|---|---|
| NCT03625505 | Venetoclax Gilteritinib | BCL-2 FLT3mut |
1b | 64 | r/r AML |
| NCT04140487 | Venetoclax Gilteritinib Azacitidine |
BCL-2 FLT3mut DNA methylation |
1/2 | 42 | r/r AML |
| NCT04336982 | CC-9009 Gilteritinib |
Cereblon E3 Ligase FLT3-ITD |
1/2 | 66 | r/r AML |
| NCT03735875 | Venetoclax Quizartinib | BCL-2 FLT3-ITD |
1/2 | 32 | r/r AML |
| NCT03661307 | Venetoclax Quizartinib Decitabine |
BCL-2 FLT3-ITD DNA methylation |
1/2 | 52 | r/r AML 1L AML unfit |
| NCT03552029 | Milademetan Quizartinib |
MDM2 FLT3-ITD |
1 | 156 | r/r AML 1L AML unfit |
| NCT03135054 | Omacetaxine Quizartinib |
Protein translation FLT3-ITD |
2 | 40 | r/r AML 1L AML |
| NCT03063944 | OPB-111077 Venetoclax Decitabine |
STAT3 BCL-2 DNA methylation |
1 | 59 | r/r AML 1L AML |
| NCT03132454 | Palbociclib Sorafenib |
CDK4/6 FLT3-ITD |
1 | 54 | r/r AML |
| NCT03008187 | SEL24 | Pan-PIM FLT3mut |
1/2 | 45 | r/r AML |
Abbreviations: 1L, first line; BCL-2, B-cell lymphoma 2; CDK4/6, cyclin dependent kinase 4/6; FLT3mut, activating FLT3 mutation; ITD, internal tandem duplication; MDM2, mouse double minute homolog 2; PIM, serine/threonine-protein kinase; r/r AML, relapsed or refractory AML; STAT3, signal transducer and activator of transcription 3.